AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
https://www.zacks.com/stock/news/2295441/abbvie-abbv-gets-chmp-nod-for-lymphoma-drug-s-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295441
Jul 01, 2024 - AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
0
Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
https://www.zacks.com/stock/news/2295379/merck-mrk-gets-chmp-nod-for-pah-drug-winrevair-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2295379
Jul 01, 2024 - Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
0
2 Incredible Dividend Growth Stocks to Buy Right Now
https://www.fool.com/investing/2024/06/27/2-incredible-dividend-growth-stocks-to-buy-right-n/?source=iedfolrf0000001
Jun 27, 2024 - These two dividend growth stocks can level up your portfolio.
0
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2293171/johnson-johnson-jnj-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2293171
Jun 25, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
0
Is Johnson & Johnson the Best Dividend Stock for You?
https://www.fool.com/investing/2024/06/25/is-johnson-johnson-the-best-dividend-stock-for-you/?source=iedfolrf0000001
Jun 25, 2024 - J&J is the textbook blue chip stock -- but it's not for everyone.
0
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
https://www.zacks.com/stock/news/2291505/pharma-stock-roundup-fda-nod-to-mrk-s-new-jab-expanded-use-of-abbv-azn-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2291505
Jun 21, 2024 - FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
0
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
https://www.zacks.com/stock/news/2291318/j-j-jnj-seeks-expanded-use-of-tremfya-for-crohn-s-disease?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291318
Jun 21, 2024 - J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
0
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
https://www.zacks.com/stock/news/2290782/here-s-why-eli-lilly-lly-is-probably-the-best-drug-stock-now?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2290782
Jun 20, 2024 - Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
0
3 No-Brainer Stocks to Buy With $500 Right Now
https://www.fool.com/investing/2024/06/19/3-no-brainer-stocks-to-buy-with-500-right-now/?source=iedfolrf0000001
Jun 19, 2024 - A modest amount of money can go a long when when it's put to work in game-changing businesses with well-defined catalysts.
0
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2290085/johnson-johnson-jnj-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2290085
Jun 18, 2024 - In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
0